Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

2,878 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Safety and efficacy of talacotuzumab plus decitabine or decitabine alone in patients with acute myeloid leukemia not eligible for chemotherapy: results from a multicenter, randomized, phase 2/3 study.
Montesinos P, Roboz GJ, Bulabois CE, Subklewe M, Platzbecker U, Ofran Y, Papayannidis C, Wierzbowska A, Shin HJ, Doronin V, Deneberg S, Yeh SP, Ozcan MA, Knapper S, Cortes J, Pollyea DA, Ossenkoppele G, Giralt S, Döhner H, Heuser M, Xiu L, Singh I, Huang F, Larsen JS, Wei AH. Montesinos P, et al. Among authors: cortes j. Leukemia. 2021 Jan;35(1):62-74. doi: 10.1038/s41375-020-0773-5. Epub 2020 Mar 16. Leukemia. 2021. PMID: 32203138 Free PMC article. Clinical Trial.
Troxacitabine activity in extramedullary myeloid leukemia.
Alvarado Y, Kantarjian HM, Cortes JE, Apostolidou E, Bivins C, Giles FJ. Alvarado Y, et al. Among authors: cortes je. Hematology. 2002 Jun;7(3):179-85. doi: 10.1080/1024533021000008155. Hematology. 2002. PMID: 12243982 Free article. Clinical Trial.
Advanced-phase chronic myeloid leukemia.
Cortes J, Kantarjian H. Cortes J, et al. Semin Hematol. 2003 Jan;40(1):79-86. doi: 10.1053/shem.2003.50005. Semin Hematol. 2003. PMID: 12563614 Review.
A randomized trial of liposomal daunorubicin and cytarabine versus liposomal daunorubicin and topotecan with or without thalidomide as initial therapy for patients with poor prognosis acute myelogenous leukemia or myelodysplastic syndrome.
Cortes J, Kantarjian H, Albitar M, Thomas D, Faderl S, Koller C, Garcia-Manero G, Giles F, Andreeff M, O'Brien S, Keating M, Estey E. Cortes J, et al. Cancer. 2003 Mar 1;97(5):1234-41. doi: 10.1002/cncr.11180. Cancer. 2003. PMID: 12599230 Free article. Clinical Trial.
2,878 results